Sagimet Biosciences Inc. Series A Common Stock (SGMT) Stock Forecast & Price Target
Sagimet Biosciences Inc. Series A Common Stock · NASDAQ
$10.70-0.24 (-2.19%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Sagimet Biosciences Inc. Series A Common Stock, 5 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $8.00 to $56.00 (about 7.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $29.33 sits 174% above the current $10.70. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.30 next quarter toward $-1.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy583%
Hold117%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Sagimet Biosciences Inc. Series A Common Stock.
As of Sep, 5 of 6 firms rate SGMT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SGMT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.30
Range $-0.35 – $-0.22 · 8 analysts · +3% YoY
Next period, 8 analysts expect Sagimet Biosciences Inc. Series A Common Stock to earn $-0.30 a share (range $-0.35 – $-0.22), versus $-0.29 a year earlier. Full-year consensus is $-1.20, growing to $-1.38 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $7.8M next year.
Top analysts covering Sagimet Biosciences Inc. Series A Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SGMT.
#1
Jonathan Wolleben
JMP Securities · Rank #29
Buy
$12.00+12.1% to target
Overall win rate
47%
+ Follow
#2
Ed Arce
HC Wainwright & Co. · Rank #132
Buy
$32.00+199.1% to target
Overall win rate
44%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #188
Buy
$67.00+526.2% to target
Overall win rate
33%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co. · Rank #221
Buy
$29.00+171.0% to target
Overall win rate
42%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #360
Buy
$33.00+208.4% to target
Overall win rate
33%
+ Follow
SGMT stock forecast FAQ
What is SGMT's average 12-month price target?+
The 6 analysts with a live target average $29.33 for Sagimet Biosciences Inc. Series A Common Stock over the next 12 months, ranging from a $56.00 high to a $8.00 low.
Is SGMT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 5 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SGMT?+
The Street-high target is $56.00 (Canaccord Genuity), and the Street-low is $8.00 (Barclays). The average of all 6 active targets is $29.33.
How many Wall Street analysts cover SGMT?+
6 analysts have an active rating on Sagimet Biosciences Inc. Series A Common Stock, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering SGMT?+
Among analysts who currently cover SGMT, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $12.00 target.
What is Sagimet Biosciences Inc. Series A Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.30 per share (range $-0.35 – $-0.22) across 8 analysts. Full-year EPS is projected at $-1.20, rising to $-1.38 the following year.
How much revenue is Sagimet Biosciences Inc. Series A Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $7.8M next year.
Have analysts been upgrading or downgrading SGMT lately?+
As of Sep, 5 of 6 firms rate SGMT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SGMT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
